Skip to content

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Cover of the July 2023 Issue of Circulation, an AHA Journal

Our peptide chemistry team is excited to announce a new publication in the journal “Circulation”, which highlights the outcome of a highly successful drug discovery collaboration with Merck & co.’s world-class drug discovery group (Kenilworth, New Jersey).

We are proud for having been part of this exciting and pioneering adventure in the field of macrocycles targeting PPI. This work validates the approach of using peptide libraries from mRNA display technologies for the identification of novel oral therapeutic agents, exemplified by the invention of MK-0616. This oral PCSK9 inhibitor has the potential to be a highly effective cholesterol lowering therapy for patients.

Image of two chemical structures, the last being MK-0616




Back To Top